Clinical trial
Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic…
NCT00471146 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00471146 |
|---|---|
| Title | Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer. |
| Official title | A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer. |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Pancreatic Ductal |
| Intervention type | Drug |
| Interventions | AG-013736, Gemcitabine, placebo |
| Enrollment | 630 |
| Start date | Jul 1, 2007 |
| Primary completion | Jan 1, 2009 |
| Completion | Nov 1, 2010 |
| First posted | May 9, 2007 |
| Last update posted | Jul 16, 2012 |
| Countries | Argentina, Australia, Austria, Belgium, Canada, France, Germany, Hong Kong, Hungary, India, Ireland, Italy and 12 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: